下载澳门新葡亰官网app_诚信官网-welcome

0571-56050590

    免疫治疗的美丽与哀愁

    免疫治疗的美丽与哀愁 金向宇 近几年来,伴随着国际上开发肿瘤免疫治疗的浪潮,我国肿瘤免疫治疗发展也非常迅速。2018年美国免疫学家James Allison和日本生物学家本庶佑因为“发现负性免疫调节治疗肿瘤的疗法”而获得了诺贝尔生理学或医学奖,得益于现今的网络和通讯的高度发达,一瞬间,似乎大部分老百姓都知道了肿瘤免疫治疗,知道了PD-1,并奉之为抗肿瘤的神药,是癌症治疗的最后一招。 事实上并非如此。虽然免疫治疗适应症广泛、副作用小,但其存在三方面的缺点: ⑴ 从有效率上来说,单药免疫治疗有效率不高。如美国第一个上市的PD-1抑制剂Nivolumab (O...

    了解详细>>
    西雅图基因与基因泰克达成合作协议

    7月24日,美国生物科技公司Seattle Genetics表示,公司与罗氏制药子公司基因泰克达成了一项临床研究合作协议,双方将进行处在研究中的抗体偶联药物(ADC)SGN-LIV1A同atezolizumab (TECENTRIQ®)的联用研究,用于治疗转移性三阴性乳腺癌(TNBC)。SGN-LIV1A是Seattle Genetics公司旗下的处在实体瘤治疗开发阶段的四个抗体偶联药物之一,该ADC药物由靶向LIV-1的单克隆抗体与细胞毒的单甲基阿里他汀E(MMAE)连接组成。 乳腺癌是女性患者最常见的癌症类型,据估计每年的乳腺癌新发病人数为170万,其中15%-20%的患者属于三阴性类型,这意味...

    了解详细>>
    英国国家健康院出具T-DM1技术指南(Technology appraisal guidance for T-DM1 by NICE of UK)

    Descriptionof the technology Trastuzumab emtansine (Kadcyla;Roche) is an antibody?drug conjugate consisting of trastuzumab linked tomaytansine, which is a cytotoxic agent. Because the antibody targets humanepidermal growth factor receptor 2 (HER2), and HER2 is overexpressed inbreast cancer cells, the conjugate delivers the toxin directly to the cancercells. Marketingauthorisation Trastuzumab emtansine, as asingle agent, has a UK marketing authorisation 'for the treatmen...

    了解详细>>
    ADC药物T-DM1作为早期乳腺癌的治疗

    Substitutingan antibody-drug conjugate of trastuzumab with the cytotoxic compound DM1(T-DM1, Kadcyla) for trastuzumab (Herceptin) as neoadjuvant therapy resulted ina high rate of pathologic complete response (pCR)without the need for chemotherapy in some patients with early HER2-positivebreast cancer, researchers reported. After12 weeks of therapy, 41% of patients treated with T-DM1, and 41.5% of thosetreated with T-DM1 plus endocrine therapy (ET), achieved pCR,compared with 15% of those treated...

    了解详细>>
    Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates—Mechanism(抗体–卡奇霉素偶联物造成肝脏微血管损伤和血小板减少的机理))

    Purpose:Adverse reactions reported in patients treated withantibody–calicheamicin conjugatessuch as gemtuzumab ozogamicin (Mylotarg)and inotuzumab ozogamicin include thrombocytopeniaand sinusoidalobstruction syndrome (SOS). Theobjective ofthis experimental work was to investigate the mechanismfor thrombocytopenia,characterize the liver injury, andidentify potentialsafety biomarkers.Experimental Design: Cynomolgus monkeys were dosed intravenouslyat 6mg/m2/dose once every 3 weeks witha nonbindinga...

    了解详细>>
    Pfizer’s leukaemia drug set to return (辉瑞治疗白血病的ADC药物Mylotarg回归美国上市))

    Pfizer’s Mylotarg looks set for a return to the US marketafter FDA advisers recommended its use in acute myeloid leukaemia.Thedrug comes with a fascinating history, and in many ways wasa precursor to today’s legions of targeted cancer drugs approved with onlyearly-stage data.Firstapproved in 2000, Mylotarg was the world’s first antibody-drug conjugate, and the first treatment in 15years for AML.Itwas also the first drug cleared under the FDA’s accelerated approvalsprocess to be withdra...

    了解详细>>